Bristol-Myers Squibb Company (BMY) Free Cash Flow Yield: 10.43%
Is Bristol-Myers Squibb Company’s free cash flow yield high or low?
Bristol-Myers Squibb Company's free cash flow yield of 10.43% is in line with its 5-year average of 10.96%, around the middle of its 5-year range (7.30%–16.78%).
The free cash flow yield for Bristol-Myers Squibb Company (BMY) is 10.43% as of Wednesday, June 10, 2026. It is below its 12-month average by 21.63% (13.31%).
BMY Free Cash Flow Yield Chart
BMY Average Free Cash Flow Yield Chart
BMY Current vs Average Free Cash Flow Yield Chart
BMY Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
10.43%
FREE CASH FLOW YIELD AVG TTM
13.31%
FREE CASH FLOW YIELD AVG 3Y
12.26%
FREE CASH FLOW YIELD AVG 5Y
10.96%
FREE CASH FLOW YIELD AVG 10Y
8.13%
FREE CASH FLOW YIELD AVG 15Y
7.24%
FREE CASH FLOW YIELD AVG 20Y
6.78%
CURRENT VS TTM AVG
-21.63%
CURRENT VS 3Y AVG
-14.95%
CURRENT VS 5Y AVG
-4.84%
CURRENT VS 10Y AVG
+28.31%
CURRENT VS 15Y AVG
+44.02%
CURRENT VS 20Y AVG
+53.81%
BMY Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $114.14B | 10.43% | 13.31% | 12.26% | 10.96% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 3.31% | 3.05% | 3.42% | 3.85% |
| CVS Health Corporation (CVS) | $125.16B | 5.89% | 6.53% | 9.25% | 10.66% |
| Medtronic plc (MDT) | $103.04B | 5.25% | 4.52% | 4.48% | 4.31% |
| Danaher Corporation (DHR) | $130.25B | 4.03% | 3.49% | 3.47% | 3.67% |
| Elevance Health Inc. (ELV) | $87.43B | 7.27% | 5.89% | 5.04% | 6.07% |
| Pfizer Inc. (PFE) | $146.36B | 6.45% | 7.35% | 5.93% | 7.34% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 1.90% | 1.28% | 0.87% | 1.09% |
| Cigna Corporation (CI) | $78.25B | 9.80% | 8.62% | 9.50% | 9.22% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 6.70% | 6.08% | 7.45% | 8.69% |
Yield Comparison
FCF Yield
10.43%
Earnings Yield
6.37%
Dividend Yield
4.47%
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
Bristol-Myers Squibb Company Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Free Cash Flow Yield FAQ
- What is the free cash flow yield for Bristol-Myers Squibb Company (BMY)?
- The free cash flow yield for BMY stock is 10.43%.
- Is Bristol-Myers Squibb Company's free cash flow yield high or low?
- Bristol-Myers Squibb Company's free cash flow yield of 10.43% is in line with its 5-year average of 10.96%, around the middle of its 5-year range (7.30%–16.78%).
- What is the TTM average free cash flow yield for Bristol-Myers Squibb Company (BMY)?
- The TTM average free cash flow yield for BMY stock is 13.31%.
- What is the 3Y average free cash flow yield for Bristol-Myers Squibb Company (BMY)?
- The 3Y average free cash flow yield for BMY stock is 12.26%.
- What is the 5Y average free cash flow yield for Bristol-Myers Squibb Company (BMY)?
- The 5Y average free cash flow yield for BMY stock is 10.96%.
- What is the 10Y average free cash flow yield for Bristol-Myers Squibb Company (BMY)?
- The 10Y average free cash flow yield for BMY stock is 8.13%.
- What is the 15Y average free cash flow yield for Bristol-Myers Squibb Company (BMY)?
- The 15Y average free cash flow yield for BMY stock is 7.24%.
- What is the 20Y average free cash flow yield for Bristol-Myers Squibb Company (BMY)?
- The 20Y average free cash flow yield for BMY stock is 6.78%.
Bristol-Myers Squibb Company Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2026-06-10 | 10.43% |
| 2026-06-09 | 10.32% |
| 2026-06-08 | 10.48% |
| 2026-06-05 | 10.17% |
| 2026-06-04 | 10.30% |
| 2026-06-03 | 10.65% |
| 2026-06-02 | 10.70% |
| 2026-06-01 | 10.60% |
| 2026-05-29 | 10.19% |
| 2026-05-28 | 10.24% |
| 2026-05-27 | 10.13% |
| 2026-05-26 | 10.04% |
| 2026-05-22 | 9.80% |
| 2026-05-21 | 9.78% |
| 2026-05-20 | 9.95% |
| 2026-05-19 | 9.99% |
| 2026-05-18 | 10.17% |
| 2026-05-15 | 10.22% |
| 2026-05-14 | 10.27% |
| 2026-05-13 | 10.33% |
| 2026-05-12 | 10.32% |
| 2026-05-11 | 10.47% |
| 2026-05-08 | 10.37% |
| 2026-05-07 | 10.36% |
| 2026-05-06 | 10.31% |
| 2026-05-05 | 10.24% |
| 2026-05-04 | 10.15% |
| 2026-05-01 | 10.01% |
| 2026-04-30 | 9.62% |
| 2026-04-29 | 10.93% |
| 2026-04-28 | 10.80% |
| 2026-04-27 | 10.89% |
| 2026-04-24 | 10.72% |
| 2026-04-23 | 10.66% |
| 2026-04-22 | 10.71% |
| 2026-04-21 | 10.59% |
| 2026-04-20 | 10.64% |
| 2026-04-17 | 10.46% |
| 2026-04-16 | 10.67% |
| 2026-04-15 | 10.87% |
| 2026-04-14 | 10.83% |
| 2026-04-13 | 10.83% |
| 2026-04-10 | 10.74% |
| 2026-04-09 | 10.58% |
| 2026-04-08 | 10.63% |
| 2026-04-07 | 10.92% |
| 2026-04-06 | 10.60% |
| 2026-04-02 | 10.56% |
| 2026-04-01 | 10.19% |
| 2026-03-31 | 10.37% |
| 2026-03-30 | 10.54% |
| 2026-03-27 | 10.75% |
| 2026-03-26 | 10.59% |
| 2026-03-25 | 10.67% |
| 2026-03-24 | 10.96% |
| 2026-03-23 | 11.04% |
| 2026-03-20 | 10.95% |
| 2026-03-19 | 10.83% |
| 2026-03-18 | 10.60% |
| 2026-03-17 | 10.54% |
| 2026-03-16 | 10.54% |
| 2026-03-13 | 10.65% |
| 2026-03-12 | 10.67% |
| 2026-03-11 | 10.49% |
| 2026-03-10 | 10.47% |
| 2026-03-09 | 10.38% |
| 2026-03-06 | 10.44% |
| 2026-03-05 | 10.36% |
| 2026-03-04 | 10.10% |
| 2026-03-03 | 10.28% |
| 2026-03-02 | 10.09% |
| 2026-02-27 | 10.09% |
| 2026-02-26 | 10.30% |
| 2026-02-25 | 10.27% |
| 2026-02-24 | 10.21% |
| 2026-02-23 | 10.28% |
| 2026-02-20 | 10.37% |
| 2026-02-19 | 10.44% |
| 2026-02-18 | 10.54% |
| 2026-02-17 | 10.43% |
| 2026-02-13 | 10.36% |
| 2026-02-12 | 10.52% |
| 2026-02-11 | 10.50% |
| 2026-02-10 | 12.33% |
| 2026-02-09 | 12.36% |
| 2026-02-06 | 12.11% |
| 2026-02-05 | 12.61% |
| 2026-02-04 | 13.04% |
| 2026-02-03 | 13.40% |
| 2026-02-02 | 13.44% |
| 2026-01-30 | 13.64% |
| 2026-01-29 | 13.83% |
| 2026-01-28 | 13.76% |
| 2026-01-27 | 13.51% |
| 2026-01-26 | 13.76% |
| 2026-01-23 | 13.74% |
| 2026-01-22 | 13.66% |
| 2026-01-21 | 13.77% |
| 2026-01-20 | 13.85% |
| 2026-01-16 | 13.59% |
| 2026-01-15 | 13.26% |
| 2026-01-14 | 13.18% |
| 2026-01-13 | 13.42% |
| 2026-01-12 | 13.46% |
| 2026-01-09 | 13.44% |
| 2026-01-08 | 13.44% |
| 2026-01-07 | 13.25% |
| 2026-01-06 | 13.79% |
| 2026-01-05 | 14.14% |
| 2026-01-02 | 14.04% |
| 2025-12-31 | 13.93% |
| 2025-12-30 | 13.85% |
| 2025-12-29 | 13.87% |
| 2025-12-26 | 13.74% |
| 2025-12-24 | 13.72% |
| 2025-12-23 | 13.83% |
| 2025-12-22 | 13.74% |
| 2025-12-19 | 13.85% |
| 2025-12-18 | 14.08% |
| 2025-12-17 | 14.03% |
| 2025-12-16 | 13.85% |
| 2025-12-15 | 13.83% |
| 2025-12-12 | 14.33% |
| 2025-12-11 | 14.66% |
| 2025-12-10 | 14.66% |
| 2025-12-09 | 14.81% |
| 2025-12-08 | 14.53% |
| 2025-12-05 | 14.39% |
| 2025-12-04 | 14.45% |
| 2025-12-03 | 14.73% |
| 2025-12-02 | 15.55% |
| 2025-12-01 | 15.27% |
| 2025-11-28 | 15.27% |
| 2025-11-26 | 15.24% |
| 2025-11-25 | 15.31% |
| 2025-11-24 | 15.72% |
| 2025-11-21 | 16.23% |
| 2025-11-20 | 16.34% |
| 2025-11-19 | 16.39% |
| 2025-11-18 | 15.95% |
| 2025-11-17 | 16.05% |
| 2025-11-14 | 16.10% |
| 2025-11-13 | 15.43% |
| 2025-11-12 | 15.29% |
| 2025-11-11 | 15.41% |
| 2025-11-10 | 15.90% |
| 2025-11-07 | 16.08% |
| 2025-11-06 | 16.10% |
| 2025-11-05 | 16.16% |
| 2025-11-04 | 16.47% |
| 2025-11-03 | 16.31% |
| 2025-10-31 | 16.29% |
| 2025-10-30 | 16.45% |
| 2025-10-29 | 16.78% |
| 2025-10-28 | 16.69% |
| 2025-10-27 | 16.47% |
| 2025-10-24 | 16.31% |
| 2025-10-23 | 16.31% |
| 2025-10-22 | 16.10% |
| 2025-10-21 | 16.05% |
| 2025-10-20 | 16.42% |
| 2025-10-17 | 16.39% |
| 2025-10-16 | 16.47% |
| 2025-10-15 | 16.39% |
| 2025-10-14 | 16.34% |
| 2025-10-13 | 16.42% |
| 2025-10-10 | 16.26% |
| 2025-10-09 | 16.00% |
| 2025-10-08 | 16.05% |
| 2025-10-07 | 16.03% |
| 2025-10-06 | 15.85% |
| 2025-10-03 | 15.75% |
| 2025-10-02 | 15.65% |
| 2025-10-01 | 15.08% |
| 2025-09-30 | 15.87% |
| 2025-09-29 | 16.21% |
| 2025-09-26 | 16.21% |
| 2025-09-25 | 16.47% |
| 2025-09-24 | 16.21% |
| 2025-09-23 | 15.92% |
| 2025-09-22 | 15.90% |
| 2025-09-19 | 15.90% |
| 2025-09-18 | 15.70% |
| 2025-09-17 | 15.50% |
| 2025-09-16 | 15.43% |
| 2025-09-15 | 15.43% |
| 2025-09-12 | 15.48% |
| 2025-09-11 | 15.04% |
| 2025-09-10 | 15.17% |
| 2025-09-09 | 15.15% |
| 2025-09-08 | 15.31% |
| 2025-09-05 | 15.17% |
| 2025-09-04 | 15.31% |
| 2025-09-03 | 15.06% |
| 2025-09-02 | 15.08% |
| 2025-08-29 | 15.15% |
| 2025-08-28 | 15.27% |
| 2025-08-27 | 15.02% |
| 2025-08-26 | 15.15% |
| 2025-08-25 | 15.17% |
| 2025-08-22 | 14.93% |
| 2025-08-21 | 14.77% |
| 2025-08-20 | 14.81% |
| 2025-08-19 | 14.79% |
| 2025-08-18 | 14.84% |
| 2025-08-15 | 14.77% |
| 2025-08-14 | 14.97% |
| 2025-08-13 | 14.95% |
| 2025-08-12 | 15.36% |
| 2025-08-11 | 15.58% |
| 2025-08-08 | 15.58% |
| 2025-08-07 | 15.77% |
| 2025-08-06 | 15.95% |
| 2025-08-05 | 15.60% |
| 2025-08-04 | 15.75% |
| 2025-08-01 | 16.18% |
| 2025-07-31 | 16.53% |
| 2025-07-30 | 13.97% |
| 2025-07-29 | 13.72% |
| 2025-07-28 | 13.51% |
| 2025-07-25 | 13.26% |
| 2025-07-24 | 13.12% |
| 2025-07-23 | 13.12% |
| 2025-07-22 | 13.39% |
| 2025-07-21 | 13.76% |
| 2025-07-18 | 13.57% |
| 2025-07-17 | 13.37% |
| 2025-07-16 | 13.62% |
| 2025-07-15 | 13.83% |
| 2025-07-14 | 13.57% |
| 2025-07-11 | 13.72% |
| 2025-07-10 | 13.25% |
| 2025-07-09 | 13.48% |
| 2025-07-08 | 13.66% |
| 2025-07-07 | 13.81% |
| 2025-07-03 | 13.70% |
| 2025-07-02 | 13.50% |
| 2025-07-01 | 13.51% |
| 2025-06-30 | 13.87% |
| 2025-06-27 | 13.87% |
| 2025-06-26 | 13.77% |
| 2025-06-25 | 13.76% |
| 2025-06-24 | 13.66% |
| 2025-06-23 | 13.70% |
| 2025-06-20 | 13.72% |
| 2025-06-18 | 13.72% |
| 2025-06-17 | 13.61% |
| 2025-06-16 | 13.21% |
| 2025-06-13 | 12.92% |
| 2025-06-12 | 12.67% |
| 2025-06-11 | 12.80% |
| 2025-06-10 | 12.85% |
| 2025-06-09 | 13.11% |
| 2025-06-06 | 13.26% |
| 2025-06-05 | 13.42% |
| 2025-06-04 | 13.40% |
| 2025-06-03 | 13.35% |
| 2025-06-02 | 13.18% |
| 2025-05-30 | 13.30% |
| 2025-05-29 | 13.42% |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner